

PODCAST

ESMO20 YO for YO: highlights on upper GI tumours

C. Cardone^{1*}, R. Pihlak² & E. Smyth³

¹Experimental Clinical Abdominal Oncology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy; ²The Christie NHS Foundation Trust, Manchester; ³Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Available online xxx

[Click here to listen to the Podcast](#)

Recent data presented at ESMO 2020 have shown that checkpoint inhibitors may have a beneficial role in the treatment of patients with oesophageal and gastric cancer.

In this podcast, Dr Claudia Cardone interviews Dr Elizabeth Smyth for highlights on upper gastrointestinal tumours, following the ESMO 2020 Virtual Congress.

Dr Smyth comments on the practice-changing data from KEYNOTE 590 and CHECKMATE 649 trials, both investigating the addition of immunotherapy to first line chemotherapy, and from CHECKMATE 577, assessing the efficacy of immunotherapy as adjuvant treatment in patients with oesophageal cancer. The three studies are discussed in the context of current treatment options, future treatment strategies, and implication for patient selection.

FUNDING

None.

DISCLOSURE

The authors declare there are no competing interests in regards to this podcast. ES reports personal financial

interests (lecture honoraria, advisory boards, travel support) from Aptitude Health, Astra Zeneca, BMS, Celgene, Elsevier, Everest Clinical Research, First Word Group, Five Prime Therapeutics, Gritstone Oncology, Imedex, Merck, My Personal Therapeutics, Roche, Sai-Med, Servier, Zymeworks outside the submitted work.

FURTHER READING

Kato K, Jun J-M, Shah MA, et al. LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study. *Ann Oncol.* 2020;31(suppl 4):S1192-S1193.

Kelly RJ, Ajani JA, Kuzdzal J, et al. LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study. *Ann Oncol.* 2020;31(suppl 4):S1193-S1194.

Moehler M, Shitara K, Garrido M, et al. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. *Ann Oncol.* 2020;31(suppl 4):S1191.

*Correspondence to: Dr Claudia Cardone, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Napoli, Italy.

E-mail: claudia.cardone@istitutotumori.na.it (C. Cardone).

2059-7029/© 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).